Alyeska Investment Group
MXCT icon

Alyeska Investment Group’s MaxCyte MXCT Stock Holding History

Alyeska Investment Group’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-166,630
Closed -$520K – 615
2023
Q3 		$520K Hold
166,630
– – ﹤0.01% 447
2023
Q2 		$765K Buy
+166,630
New +$766K 0.01% 472
2021
Q4 		– Sell
-125,000
Closed -$1.53M – 690
2021
Q3 		$1.53M Buy
+125,000
New +$1.88M 0.02% 537

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's MXCT Position: Q4 2023 in Review

Alyeska Investment Group sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 166,630 shares — an estimated $520K sold.

Alyeska Investment Group first reported a position in MXCT in Q3 2021 and held it in 3 quarters. The position peaked at $1.53M in Q3 2021. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

  • Alyeska Investment Group reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 166,630 MaxCyte shares in Q4 2023, an estimated $520K.
  • Alyeska Investment Group first reported a position in MaxCyte in Q3 2021 and held it in 3 quarters.
  • Alyeska Investment Group's MaxCyte position peaked at $1.53M in Q3 2021.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on Alyeska Investment Group's 13F filing for Q4 2023, filed 14 Feb 2024.